PPT-M inimal R esidual D isease in AML

Steven M Kornblau MD Department of Leukemia Department of Stem Cell Transplantation and Cellular Therapy The MRD Concept Most patients achieve remission Most relapse Cure rate 2025 overall therefore 23. I. n The name of God. . CD 117, C- kit. CD117 is a 145 . kD. protein tyrosine . kinase. also known as c-Kit.. Receptor for stem cell factor . or c-Kit . ligand. .. . CD117 is expressed on . pluripotent. Elie Traer. September 13, 2012. Outline. Genetic tests and methodology. Cytogenetics. , i.e. large chromosomal abnormalities. FISH, smaller chromosomal changes. Genetic mutations. AML. Evolution of genetic tests in diagnosis and prognosis. Staphylococcus . aureus. On Door Handles In . Ahmadu. Bello University, Zaria, Nigeria.. Onaolapo. . J. A. .*, . Afolabi. . O. . E . and . Igwe. J. . C.. Department . of Pharmaceutics and Pharmaceutical Microbiology, . Sanctions”. Presented by The Bahamas Association of Compliance Officers (BACO). Understanding Sanctions . Yolanda M. Hilton. Compliance Director/MLRO. Intertrust. (Bahamas) Limited. Enforcing AML Compliance with sanctions. THE FATF RECOMMENDATIONS. Presented by . ERM Institute. 1. A. AML/CFT POLICIES AND COORDINATION. . 2. THE FATF RECOMMENDATIONS. Assessing risks and applying a risk-based approach *. Countries should identify, assess, and understand the money laundering and terrorist financing risks for the country, and should take action, including designating an authority or mechanism to coordinate actions to assess risks, and apply resources, aimed at ensuring the risks are mitigated effectively. Based on that assessment, countries should apply a risk-based approach (RBA) to ensure that measures to prevent or mitigate money laundering and terrorist financing are commensurate with the risks identified. This approach should be an. R. esidual . D. isease in AML. Steven M. Kornblau, M.D.. Department of Leukemia. Department of Stem Cell Transplantation and Cellular Therapy. The MRD Concept. Most patients achieve remission. Most relapse. Farhad. . Ravandi. , . MD. Professor of Medicine. University of Texas MD Anderson Cancer Center. Disclosure of Conflicts of Interest. Dr. . Ravandi. discloses that he is a consultant/advisor for Pfizer, . Jung/. Shlush. Department . of Immunology. . Objectives of the seminar. Learn about the newest research the . . . hematopoetic. system and leukemia. Identify emerging topics and techniques. Raymond E Felgar, MD, PhD. University of Pittsburgh, Pittsburgh, PA. 45-year-old man with recent history of shingles, night sweats and gum swelling.. Hematologic testing showed the following:. WBC 69,300 / Hgb 23.5 / Platelets = 114,000. Ross . L. Levine M.D.. Human Oncology and Pathogenesis Program. Leukemia Service, Department of Medicine. Memorial Sloan Kettering Cancer Center. Weill Cornell School of Medicine. Acute Myeloid Leukemia . Spencer W. . Doak. , Director for BSA / AML Policy, . Office of the Comptroller of the Currency (OCC).  . Sarah Green. , Senior Director, Enforcement and BSA Policy, . Financial Industry Regulatory Authority (FINRA). and Interpreting Results. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. . approach for obtaining stable &. accurate low-order . projection-based reduced order models for nonlinear . compressible flow. Irina Tezaur. 1. , . Maciej. Balajewicz. 2. 1. Quantitative Modeling & Analysis Department, Sandia National Laboratories. Daver. 7 + 3 . Thank you . Jk. . Basic Facts . Unbridled proliferation of hematopoietic stem cells (myeloid linage) resulting in marrow failure and patient death unless successfully treated. 20 K new US cases with 10 K death annually.